Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EMEND

« Back to Dashboard
Emend is a drug marketed by Merck and Merck And Co Inc and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has two hundred and nine patent family members in fifty-two countries.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are five drug master file entries for this compound. One supplier is listed for this compound. There is one tentative approval for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

Summary for Tradename: EMEND

Patents:5
Applicants:2
NDAs:2
Suppliers / Packagers: see list15

Clinical Trials for: EMEND

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting

Efficacy of Aprepitant (Emend®) in Children
Status: Recruiting Condition: Nausea; Vomiting; Childhood Cancer

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Status: Not yet recruiting Condition: Non-small Cell Lung Cancer; Vomiting; Nausea; Emesis

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
Status: Recruiting Condition: HIV Infection

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
Status: Terminated Condition: Chemotherapy-Induced Nausea and Vomiting

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen
Status: Not yet recruiting Condition: Postoperative Nausea and Vomiting

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Status: Recruiting Condition: Nausea; Vomiting; Glioma

Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006RXNo5,719,147<disabled>YY<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003RXNo8,258,132<disabled>Y<disabled>
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010RXYes5,691,336<disabled>YY<disabled>
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNNo5,691,336<disabled>YY<disabled>
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006RXNo6,096,742<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMEND

Drugname Dosage Strength RLD Submissiondate
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008

Non-Orange Book Patents for Tradename: EMEND

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists<disabled in preview>
6,638,930 Morpholine and thiomorpholine tachykinin receptor antagonists<disabled in preview>
6,235,735 Morpholine and thiomorpholine tachykinin receptor antagonists<disabled in preview>
5,637,699 Process for preparing morpholine tachykinin receptor antagonists<disabled in preview>
6,229,010 Polymorphic form of a tachykinin receptor antagonist<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EMEND

Country Document Number Publication Date
Canada2183250Mar 21, 2006
Slovenia9300346Dec 31, 1993
China1147254Apr 09, 1997
Spain2141133Mar 16, 2000
Finland963450Sep 03, 1996
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc